Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI.


Journal

American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465

Informations de publication

Date de publication:
03 2020
Historique:
received: 22 11 2018
accepted: 30 10 2019
pubmed: 21 1 2020
medline: 29 4 2020
entrez: 21 1 2020
Statut: ppublish

Résumé

Patients with non-ischemic systolic heart failure have an increased risk of sudden cardiac death (SCD). Myocardial fibrosis, detected as late gadolinium enhancement (LGE) with cardiac magnetic resonance (CMR), has been shown to predict all-cause mortality. We hypothesized that LGE can identify patients with non-ischemic heart failure who will benefit from ICD implantation. In this prospective observational sub-study of the Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heart Failure on Mortality (DANISH), 252 patients underwent CMR. LGE was quantified by the full width/half maximum method. The primary endpoint was all-cause mortality. LGE could be adequately assessed in 236 patients, median age was 61 years and median duration of heart failure was 14 months; there were 108 patients (46%) randomized to ICD. Median follow-up time was 5.3 years. Median left ventricular ejection fraction on CMR was 35%. In all, 50 patients died. LGE was present in 113 patients (48%). The presence of LGE was an independent predictor of all-cause mortality (HR 1.82; 95% CI 1.002-3.29; P = .049) after adjusting for known cardiovascular risk factors. ICD implantation did not impact all-cause mortality, for either patients with LGE (HR 1.18; 95% CI 0.59-2.38; P = .63), or for patients without LGE (HR 1.00; 95% CI 0.39-2.53; P = .99), (P for interaction =0.79). In patients with non-ischemic systolic heart failure, LGE predicted all-cause mortality. However, in this cohort, LGE did not identify a group of patients who survived longer by receiving an ICD.

Identifiants

pubmed: 31955812
pii: S0002-8703(19)30351-5
doi: 10.1016/j.ahj.2019.10.020
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-176

Subventions

Organisme : British Heart Foundation
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Marie Bayer Elming (MB)

Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address: marie.bayer.elming@regionh.dk.

Sophia Hammer-Hansen (S)

Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Inga Voges (I)

Department of Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.

Eva Nyktari (E)

Department of Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.

Anna Axelsson Raja (AA)

Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Jesper Hastrup Svendsen (JH)

Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Steen Pehrson (S)

Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

James Signorovitch (J)

Analysis Group Inc., Boston, MA, USA.

Lars Køber (L)

Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Sanjay K Prasad (SK)

Department of Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.

Jens Jakob Thune (JJ)

Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Cardiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH